
Sign up to save your podcasts
Or


The CGT Supply Chain team has collaboratively created a high-level pathway that differentiates between autologous, allogeneic, and gene therapies and the logistics pathway they follow.
Two of the subject matter experts, Alyssa Palmer, Global Value Stream Strategy at Roche, and Maria Rende, Process Technology Expert – Cell Therapy at Sartorius Stedim, who worked on the pathway, talk about their experience working in the team, the process of creating the pathway, and what they feel are the key benefits to participation.
Speakers: Alyssa Palmer, Global Value Stream Strategy at Roche, Maria Rende, Process Technology Expert – Cell Therapy at Sartorius Stedim, Antoinette Levett, Associate Account Manager, Supply Chain to Patient
In this episode, we take a look at some of the challenges that are encountered when trying to introduce digital to drug delivery devices, where the value and opportunities lie for digital, and what the future might hold for digital in combination devices.
Mark describes what could be a typical trajectory when considering adding a digital element to a drug delivery device, introducing where challenges might present themselves along a hypothetical timeline, contrasting with what might be a typical timeline for any pharmaceutical product. The reality of constantly evolving apps, boards, and software is very different from that of a 'regular' drug or biologic. The value - to patients, health care providers, industry, and many other stakeholders is also a critical aspect of including digital in drug delivery devices.
Mark goes on to describe the pros and cons associated with connected devices: the management of personal and clinical data, and the value that data can realise in enhancing patient experiences and optimising treatment and its outcomes. Mark also touches upon connected devices failures and their implications, and cites some of the key successes seen in this space to date with insulin delivery, and ways in which we can perhaps extend that success to other therapeutic areas. Mark speaks so fluently about this topic that you'll be left wanting more. Let us know if you want a sequel.
Senior BioPhorum Connect gives our senior leaders a window into what is happening across the Phorums they sponsor. Clare tells us what they can expect to hear about in the second half of this year. From the World Health Organization's Pandemic Preparedness Program to our most recent roadmaps, these easy-to-access meetings are the platforms by which to keep informed.
The update to Annex 1 is perhaps the biggest change to the manufacture of sterile medicinal products in recent times and possibly the most important topic for many in the biomanufacturing industry now. How has BioPhorum helped to prepare its members for the new regulations?
The Digital Plant Maturity Model (DPMM) is a strategic framework guiding industries through five digital maturity levels, aligning shop floor to senior management with clear targets and information. It's industry-tailored for simplicity, adopted by companies like Merck through top-down decisions, fostering a common language for digital alignment. Industry-built and peer-reviewed, the DPMM offers visibility and is a key element in digital strategy and network-wide digital progression.
In this podcast, Yves Berthouzoz, a member of the BioPhorum IT, Digital and Data leadership team discusses his role in the development of the recent DPMM refresh, how Merck has adopted the tool, and the benefits of using it to assess your plant and global network manufacturing maturity level.
Download the assessment tool, accompanying paper, and best practice guide here: Digital Plant Maturity Model V3 - BioPhorum Operations Group
With discussions around strategy and working together with the agencies and legislators to make sure the industry voice is heard on all the raft of changes we expect to see around materials of concern and new modality regulations, what has been the key focus of the last six months, and what are the critical pathways that will shape the program going forward?
With the FDA calling for greater patient diversity in clinical trials, and the industry’s need to include patients in clinical trials no matter where they are located, how can direct to patient shipment help in addressing diversity and inclusion? What are the greatest challenges that direct to patient shipments face both in terms of data privacy and regulations? Andrea tells us about how the industry is working to achieve greater patient centricity with direct to patient shipments, accelerating the clinical trial process and ultimately allowing drugs to come to market earlier, for the benefit of all.
Speakers - Dr Andrea Zobel
Senior Director Personalized Supply Chain
World Courier
We have to adjust some of our manufacturing industry's production processes to take account of changes that we see in the acceptability of different materials. These materials of concern are those that have been identified to have a negative environmental impact, as well as a negative impact on human health. Bob tells us what this means for the future of the supply chain, and the patients it serves. How does BioPhorum Supply Partner enable its members to work together on identifying ways to meet the challenge?
Following a successful meeting with senior leaders in Copenhagen, Clare tells us that the biggest theme of the week was a discussion about regulatory partnerships.
The phrase was coined, regulatory partnership, not policing. Clare tells us more about what our members need from a regulatory perspective in order to accelerate progress.
Clare tells us about the variety of topics that are explored by our senior leaders who come together to openly discuss trends, and challenges while learning how the BioPhorum teams are addressing them. It is a chance for leaders to catch-up on the work that their SMEs are doing across the BioPhorum community
From the publisher's feed